Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Gynecologic Oncology Group to begin phase II elesclomol trial in ovarian cancer

Nov. 4, 2010

Viralytics submits IND for phase II trial of Cavatak in melanoma

Nov. 4, 2010

BC-819 shows good safety profile in phase I/IIa trial in pancreatic cancer

Nov. 4, 2010

Panobinostat has antitumor activity in phase II trial in SCLC

Nov. 4, 2010

AMG-386 is active in renal cell carcinoma and ovarian cancer

Nov. 4, 2010

Genta receives EMA advice for phase III tesetaxel trial in gastric cancer

Nov. 3, 2010

Cell Therapeutics submits MAA to EMA for Pixuvri in NHL

Nov. 3, 2010

Compugen licenses MAb-based oncology target to Seattle Genetics

Nov. 3, 2010

Merck KGaA describes novel E-NPP 2 inhibitors

Nov. 3, 2010

Incuron initiates phase Ib trial of Curaxin CBLC-102 in liver tumors

Nov. 3, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...